Accelerating drug repurposing for COVID-19 via modeling drug mechanism
  of action with large scale gene-expression profiles
  The novel coronavirus disease, named COVID-19, emerged in China in December
2019, and has rapidly spread around the world. It is clearly urgent to fight
COVID-19 at global scale. The development of methods for identifying drug uses
based on phenotypic data can improve the efficiency of drug development.
However, there are still many difficulties in identifying drug applications
based on cell picture data. This work reported one state-of-the-art machine
learning method to identify drug uses based on the cell image features of 1024
drugs generated in the LINCS program. Because the multi-dimensional features of
the image are affected by non-experimental factors, the characteristics of
similar drugs vary greatly, and the current sample number is not enough to use
deep learning and other methods are used for learning optimization. As a
consequence, this study is based on the supervised ITML algorithm to convert
the characteristics of drugs. The results show that the characteristics of ITML
conversion are more conducive to the recognition of drug functions. The
analysis of feature conversion shows that different features play important
roles in identifying different drug functions. For the current COVID-19,
Chloroquine and Hydroxychloroquine achieve antiviral effects by inhibiting
endocytosis, etc., and were classified to the same community. And Clomiphene in
the same community inibited the entry of Ebola Virus, indicated a similar MoAs
that could be reflected by cell image.
